



September 12, 2005 10:00 AM US Eastern TimeZone

Correlagen Diagnostics and Children's Hospital Boston Announce Molecular Diagnostics Collaboration

BIOWIRE2K

CAMBRIDGE and BOSTON, Mass.—(BUSINESS WIRE)--September 12, 2005 - Correlagen Diagnostics Inc. and Children's Hospital Boston today announce the signing of a collaboration agreement intended to accelerate the adoption of clinically useful gene testing in patient care.

Correlagen will conduct research with members of Children's that is focused on the determination of the clinical validity of genetic testing to diagnose certain conditions and on the discovery of correlations between genetic variation and disease phenotypes. Correlagen will also develop and provide DNA-sequence assays to Children's investigators for research purposes. Correlagen has the right to commercialize diagnostic testing that arises from certain collaborative research programs.

The collaboration will leverage Correlagen's expertise in high throughput DNA sequencing and the expertise of Children's faculty members in the genes involved in certain disease areas to enable the translation of research into clinical diagnostic tests.

"This collaboration gives Children's the opportunity to participate in the selection and encourage the development of genetic testing that will have important clinical implications for our patients. Additionally, we expect Correlagen to support certain key research efforts at Children's by providing reliable, high throughput human gene sequencing" said Gary Fleisher, MD, Chief of Children's Department of Medicine.

Dr. David Margulies, Chief Executive Officer of Correlagen, said "our collaboration with Children's furthers Correlagen's mission to accelerate the use and increase the utility of genetic testing in clinical practice. Correlagen's ability to create and perform sequence-based diagnostic assays should be helpful to a broad range of research efforts and clinical needs." Joyce Samet, Senior Vice President, added, "we expect our relationship with Children's to rapidly increase the breadth of Correlagen's clinical diagnostic offerings."

Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, nine members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 347-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit:

<http://www.childrenshospital.org/research/>.

Correlagen Diagnostics, Inc. develops and commercializes genetic testing services, using a high throughput automated approach that incorporates sequencing, variant analysis and information technology. By focusing on Genes That Matter™ --genes where variation is correlated with disease and where testing would impact diagnosis and treatment--, Correlagen is accelerating and increasing the utility of genetic testing in clinical practice. Correlagen Diagnostics is based in Cambridge, Massachusetts. www.correlagen.com

Correlagen Diagnostics, Inc.
Joyce S. Samet
617-577-0152
jsamet@correlagen.com